Vir, GSK’s COVID-19 antibody treatment works against omicron in a lab study, and WHO no longer recommends convalescent plasma

Vir Biotechnology and GlaxoSmithKline’s COVID-19 antibody treatment worked against omicron in a laboratory study.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.